Epinephrine stimulates IL-6 expression in skeletal muscle and C 2C12 myoblasts: Role of c-Jun NH2-terminal kinase and histone deacetylase activity

American Journal of Physiology - Endocrinology and Metabolism

Volumn 286, Issue 5 49-5, 2004, Pages

  Frost, Robert A ^a   Nystrom, Gerald J ^a   Lang, Charles H ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

Adrenergic receptors; Interleukin 6

Indexed keywords

3 ISOPROPYLAMINO 1 (7 METHYL 4 INDANYLOXY) 2 BUTANOL; 4 (4 FLUOROPHENYL) 2 (4 HYDROXYPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ADRENALIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; CYTOKINE; DEXAMETHASONE; ENDOTOXIN; HISTONE DEACETYLASE; HORMONE; INTERLEUKIN 6; MESSENGER RNA; PHENTOLAMINE; PROPRANOLOL; STRESS ACTIVATED PROTEIN KINASE; TRICHOSTATIN A;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DOSE TIME EFFECT RELATION; ENZYME ACTIVITY; EXERCISE; MALE; MUSCLE MASS; MYOBLAST; NONHUMAN; NUTRITION; PRIORITY JOURNAL; RAT; SKELETAL MUSCLE;

ANIMALS; CELLS, CULTURED; EPINEPHRINE; HISTONE DEACETYLASES; INTERLEUKIN-6; JNK MITOGEN-ACTIVATED PROTEIN KINASES; LIPOPOLYSACCHARIDES; MALE; MITOGEN-ACTIVATED PROTEIN KINASES; MUSCLE, SKELETAL; MYOBLASTS, SKELETAL; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ADRENERGIC, BETA; RNA, MESSENGER; STRESS;

EID: 1942518730     PISSN: 01931849     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpendo.00560.2003     Document Type: Article

References (66)

1. Abbott FV and Bonder M. Options for management of acute pain in the rat. Vet Rec 140: 553-557, 1997.
2. Barbieri M, Ferrucci L, Ragno E, Corsi A, Bandinelli S, Bonafe M, Olivieri F, Giovagnetti S, Franceschi C, Guralnik JM, and Paolisso G. Chronic inflammation and the effect of IGF-I on muscle strength and power in older persons. Am J Physiol Endocrinol Metab 284: E481-E487, 2003.
3. Bergmann M, Gornikiewicz A, Sautner T, Waldmann E, Weber T, Mittlbock M, Roth E, and Fugger R. Attenuation of catecholamine-induced immunosuppression in whole blood from patients with sepsis. Shock 12: 421-427, 1999.
4. Bessey PQ, Jiang ZM, Johnson DJ, Smith RJ, and Wilmore DW. Posttraumatic skeletal muscle proteolysis: the role of the hormonal environment. World J Surg 13: 465-471, 1989.
5. Blanco-Bose WE, Yao CC, Kramer RH, and Blau HM. Purification of mouse primary myoblasts based on alpha 7 integrin expression. Exp Cell Res 265: 212-220, 2001.
6. Buck M and Chojkier M. Muscle wasting and dedifferentiation induced by oxidative stress in a murine model of cachexia is prevented by inhibitors of nitric oxide synthesis and antioxidants. EMBO J 15: 1753-1765, 1996.
7. Burger A, Benicke M, Deten A, and Zimmer HG. Catecholamines stimulate interleukin-6 synthesis in rat cardiac fibroblasts. Am J Physiol Heart Circ Physiol 281: H14-H21, 2001.
8. Carrasco GA and Van de Kar LD. Neuroendocrine pharmacology of stress. Eur J Pharmacol 463: 235-272, 2003.
9. Cesari M, Penninx BW, Newman AB, Kritchevsky SB, Nicklas BJ, Sutton-Tyrrell K, Rubin SM, Ding J, Simonsick EM, Harris TB, and Pahor M. Inflammatory markers and onset of cardiovascular events: results from the Health ABC study. Circulation 108: 2317-2322, 2003.
10. Cosma MP. Ordered recruitment: gene-specific mechanism of transcription activation. Mol Cell 10: 227-236, 2002.
11. Costelli P and Baccino FM. Mechanisms of skeletal muscle depletion in wasting syndromes: role of ATP-ubiquitin-dependent proteolysis. Curr Opin Clin Nutr Metab Care 6: 407-412, 2003.
12. Diwan A, Tran T, Misra A, and Mann DL. Inflammatory mediators and the failing heart: a translational approach. Curr Mol Med 3: 161-182, 2003.
13. Fernqvist-Forbes E, Hilding A, Ekberg K, and Brismar K. Influence of circulating epinephrine and norepinephrine on insulin-like growth factor binding protein-1 in humans. J Clin Endocrinol Metab 82: 2677-2680, 1997.
14. Ferrucci L and Guralnik JM. Inflammation, hormones, and body composition at a crossroad. Am J Med 115: 501-502, 2003.
15. Frost RA and Lang CH. Differential effects of insulin-like growth factor I (IGF-I) and IGF-binding protein-1 on protein metabolism in human skeletal muscle cells. Endocrinology 140: 3962-3970, 1999.
16. Frost RA and Lang CH. Alteration of somatotropic function by proinflammatory cytokines. J Anim Sci In press.
17. Frost RA, Nystrom GJ, and Lang CH. Stimulation of insulin-like growth factor binding protein-I synthesis by interleukin-1beta: requirement of the mitogen-activated protein kinase pathway. Endocrinology 141: 3156-3164, 2000.
18. Frost RA, Nystrom GJ, and Lang CH. Lipopolysaccharide regulates proinflammatory cytokine expression in mouse myoblasts and skeletal muscle. Am J Physiol Regul Integr Comp Physiol 283: R698-R709, 2002.
19. 2-terminal kinase. Am J Physiol Regul Integr Comp Physiol 285: R1153-R1164, 2003.
20. Frost RA, Nystrom GJ, and Lang CH. Tumor necrosis factor-alpha decreases insulin-like growth factor-I messenger ribonucleic acid expression in C2C12 myoblasts via a Jun N-terminal kinase pathway. Endocrinology 144: 1770-1779, 2003.
21. Gallucci S, Provenzano C, Mazzarelli P, Scuderi F, and Bartoccioni E. Myoblasts produce IL-6 in response to inflammatory stimuli. Int Immunol 10: 267-273, 1998.
22. Gornikiewicz A, Sautner T, Brostjan C, Schmierer B, Fugger R, Roth E, Muhlbacher F, and Bergmann M. Catecholamines up-regulate lipopolysaccharide-induced IL-6 production in human microvascular endothelial cells. FASEB J 14: 1093-1100, 2000.
23. Hargrove DM, Lang CH, Bagby GJ, and Spitzer JJ. Epinephrine-induced increase in glucose turnover is diminished during sepsis. Metabolism 38: 1070-1076, 1989.
24. Helmer KS, Cui Y, Dewan A, and Mercer DW. Ketamine/xylazine attenuates LPS-induced iNOS expression in various rat tissues. J Surg Res 112: 70-78, 2003.
25. Izevbigie EB and Bergen WG. Beta-adrenergic agonist hyperplastic effect is associated with increased fibronectin gene expression and not mitogen-activated protein kinase modulation in C2C12 cells. Proc Soc Exp Biol Med 223: 302-309, 2000.
26. Johnson GL and Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 298: 1911-1912, 2002.
27. Kami K and Senba E. Localization of leukemia inhibitory factor and interleukin-6 messenger ribonucleic acids in regenerating rat skeletal muscle. Muscle Nerve 21: 819-822, 1998.
28. Kim PK and Deutschman CS. Inflammatory responses and mediators. Surg Clin North Am 80: 885-894, 2000.
29. Kinugawa T, Kato M, Ogino K, Osaki S, Tomikura Y, Igawa O, Hisatome I, and Shigemasa C. Interleukin-6 and tumor necrosis factor-alpha levels increase in response to maximal exercise in patients with chronic heart failure. Int J Cardiol 87: 83-90, 2003.
30. Kolodziejczyk SM, Walsh GS, Balazsi K, Seale P, Sandoz J, Hierlihy AM, Rudnicki MA, Chamberlain JS, Miller FD, and Megeney LA. Activation of JNK1 contributes to dystrophic muscle pathogenesis. Curr Biol 11: 1278-1282, 2001.
31. Kondo A, Mogi M, Koshihara Y, and Togari A. Signal transduction system for interleukin-6 and interleukin-11 synthesis stimulated by epinephrine in human osteoblasts and human osteogenic sarcoma cells. Biochem Pharmacol 61: 319-326, 2001.
32. Kostyniuk CL, Dehm SM, Batten D, and Bonham K. The ubiquitous and tissue specific promoters of the human SRC gene are repressed by inhibitors of histone deacetylases. Oncogene 21: 6340-6347, 2002.
33. Lang CH. Sepsis-induced insulin resistance in rats is mediated by a β-adrenergic mechanism. Am J Physiol Endocrinol Metab 263: E703-E711, 1992.
34. Lang CH, Frost RA, Nairn AC, MacLean DA, and Vary TC. TNF-α impairs heart and skeletal muscle protein synthesis by altering translation initiation. Am J Physiol Endocrinol Metab 282: E336-E347, 2002.
35. Lang CH, Nystrom GJ, and Frost RA. Burn-induced changes in IGF-I and IGF-binding proteins are partially glucocorticoid dependent. Am J Physiol Regul Integr Comp Physiol 282: R207-R215, 2002.
36. Lang CH, Silvis C, Deshpande N, Nystrom G, and Frost RA. Endotoxin stimulates in vivo expression of inflammatory cytokines tumor necrosis factor alpha, interleukin-1beta, -6, and high-mobility-group protein-1 in skeletal muscle. Shock 19: 538-546, 2003.
37. Lang CH, Vary TC, and Frost RA. Acute in vivo elevation of insulin-like growth factor (IGF) binding protein-1 decreases plasma free IGF-I and muscle protein synthesis. Endocrinology 144: 3922-3933, 2003.
38. Laribee RN and Klemsz MJ. Loss of PU.1 expression following inhibition of histone deacetylases: J Immunol 167: 5160-5166, 2001.
39. Lieskovska J, Guo D, and Derman E. IL-6-overexpression brings about growth impairment potentially through a GH receptor defect. Growth Horm IGF Res 12: 388-398, 2002.
40. Mazzarelli P, Scuderi F, Mistretta G, Provenzano C, and Bartoccioni E. Effect of transforming growth factor-beta1 on interleukin-6 secretion in human myoblasts. J Neuroimmunol 87: 185-188, 1998.
41. Mazzeo RS, Donovan D, Fleshner M, Butterfield GE, Zamudio S, Wolfel EE, and Moore LG. Interleukin-6 response to exercise and high-altitude exposure: influence of α-adrenergic blockade. J Appl Physiol 91: 2143-2149, 2001.
42. Mishra N, Reilly CM, Brown DR, Ruiz P, and Gilkeson GS. Histone deacetylase inhibitors modulate renal disease in the MRL-lpr/lpr mouse. J Clin Invest 111: 539-552, 2003.
43. Morse D, Pischke SE, Zhou Z, Davis RJ, Flavell RA, Loop T, Otterbein SL, Otterbein LE, and Choi AM. Suppression of inflammatory cytokine production by carbon monoxide involves the JNK pathway and AP-1. J Biol Chem 278: 36993-36998, 2003.
44. Mulholland NM, Soeth E, and Smith CL. Inhibition of MMTV transcription by HDAC inhibitors occurs independent of changes in chromatin remodeling and increased histone acetylation. Oncogene 22: 4807-4818, 2003.
45. Murray DR, Prabhu SD, and Chandrasekar B. Chronic beta-adrenergic stimulation induces myocardial proinflammatory cytokine expression. Circulation 101: 2338-2341, 2000.
46. Napoli R, Gibson L, Hirshman MF, Boppart MD, Dufresne SD, Horton ES, and Goodyear LJ. Epinephrine and insulin stimulate different mitogen-activated protein kinase signaling pathways in rat skeletal muscle. Diabetes 47: 1549-1554, 1998.
47. Niebauer J, Pflaum CD, Clark AL, Strasburger CJ, Hooper J, Poole-Wilson PA, Coats AJ, and Anker SD. Deficient insulin-like growth factor I in chronic heart failure predicts altered body composition, anabolic deficiency, cytokine and neurohormonal activation. J Am Coll Cardiol 32: 393-397, 1998.
48. Papanicolaou DA, Petrides JS, Tsigos C, Bina S, Kalogeras KT, Wilder R, Gold PW, Deuster PA, and Chrousos GP. Exercise stimulates interleukin-6 secretion: inhibition by glucocorticoids and correlation with catecholamines. Am J Physiol Endocrinol Metab 271: E601-E605, 1996.
49. Penkowa M, Keller C, Keller P, Jauffred S, and Pedersen BK. Immunohistochemical detection of interleukin-6 in human skeletal muscle fibers following exercise. FASEB J 17: 2166-2168, 2003.
50. Ray A, LaForge KS, and Sehgal PB. On the mechanism for efficient repression of the interleukin-6 promoter by glucocorticoids: enhancer, TATA box, and RNA start site (Inr motif) occlusion. Mol Cell Biol 10: 5736-5746, 1990.
51. Rector E, Otto K, Kietzmann M, Nolte I, and Lehmacher W. [Pharmacokinetics and effects of xylazine (Rompun) in dogs]. Berl Munch Tierarztl Wochenschr 109: 18-22, 1996.
52. Remondino A, Kwon SH, Communal C, Pimentel DR, Sawyer DB, Singh K, and Colucci WS. Beta-adrenergic receptor-stimulated apoptosis in cardiac myocytes is mediated by reactive oxygen species/c-Jun NH2-terminal kinase-dependent activation of the mitochondrial pathway. Circ Res 92: 136-138, 2003.
53. Roubenoff R. Catabolism of aging: is it an inflammatory process? Curr Opin Clin Nutr Metab Care 6: 295-299, 2003.
54. Samstein B, Hoimes ML, Fan J, Frost RA, Gelato MC, and Lang CH. IL-6 stimulation of insulin-like growth factor binding protein (IGFBP)-1 production. Biochem Biophys Res Commun 228: 611-615, 1996.
55. Severn A, Rapson NT, Hunter CA, and Liew FY. Regulation of tumor necrosis factor production by adrenaline and beta-adrenergic agonists. J Immunol 148: 3441-3445, 1992.
56. Steensberg A, Toft AD, Schjerling P, Halkjaer-Kristensen J, and Pedersen BK. Plasma interleukin-6 during strenuous exercise: role of epinephrine. Am J Physiol Cell Physiol 281: C1001-C1004, 2001.
57. Steensberg A, van Hall G, Osada T, Sacchetti M, Saltin B, and Klarlund Pedersen B. Production of interleukin-6 in contracting human skeletal muscles can account for the exercise-induced increase in plasma interleukin-6. J Physiol 529: 237-242, 2000.
58. Suuronen T, Huuskonen J, Pihlaja R, Kyrylenko S, and Salminen A. Regulation of microglial inflammatory response by histone deacetylase inhibitors. J Neurochem 87: 407-416, 2003.
59. Tisdale MJ. Biochemical mechanisms of cellular catabolism. Curr Opin Clin Nutr Metab Care 5: 401-405, 2002.
60. Tracey KJ. Lethal weight loss: the focus shifts to signal transduction. Sci STKE: PE21, 2002.
61. Van Gool J, van Vugt H, Helle M, and Aarden LA. The relation among stress, adrenalin, interleukin 6 and acute phase proteins in the rat. Clin Immunol Immunopathol 57: 200-210, 1990.
62. Vanden Berghe W, De Bosscher K, Boone E, Plaisance S, and Haegeman G. The nuclear factor-kappaB engages CBP/p300 and histone acetyl-transferase activity for transcriptional activation of the interleukin-6 gene promoter. J Biol Chem 274: 32091-32098, 1999.
63. Ventura JJ, Kennedy NJ, Lamb JA, Flavell RA, and Davis RJ. c-Jun NH(2)-terminal kinase is essential for the regulation of AP-1 by tumor necrosis factor. Mol Cell Biol 23: 2871-2882, 2003.
64. Vicennati V, Vottero A, Friedman C, and Papanicolaou DA. Hormonal regulation of interleukin-6 production in human adipocytes. Int J Obes Relat Metab Disord 26: 905-911, 2002.
65. Wolfe RR, Jahoor F, and Hartl WH. Protein and amino acid metabolism after injury. Diabetes Metab Rev 5: 149-164, 1989.
66. Yu XN, Komaki G, Sudo N, and Kubo C. Central and peripheral catecholamines regulate the exercise-induced elevation of plasma interleukin 6 in rats. Life Sci 69: 167-174, 2001.